ArticleSubstance abuse2022
Opioid treatment programs, telemedicine and COVID-19: A scoping review.
Open access · greenAbstract readScoping Review
In one paragraph
Article in Substance abuse, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.Drug and alcohol dependence · 2025Pooled it
- Global perspectives on telemedicine-enabled medications for opioid use disorder: Practices, priorities, and barriers.Journal of telemedicine and telecare · 2026Article
- "The alternative is they're not getting care at all": a qualitative interview study of opioid use disorder treatment providers' perspectives on quality and appropriateness of telehealth for buprenorphine access.Harm reduction journal · 2026Article
- Seventeen years of experience: a retrospective cohort analysis of methadone maintenance treatment program patterns in Georgia.Harm reduction journal · 2025Article
- Medicaid Expansion Boosted Specialty Treatment Episodes For Substance Use Disorder In Expansion States, 2010-22.Health affairs (Project Hope) · 2025Article
- Buprenorphine Is Associated With Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2025Article
- Investigating heterogeneous effects of an expanded methadone access policy with opioid treatment program retention: a Rhode Island population-based retrospective cohort study.American journal of epidemiology · 2025Article
- Advocacy and the Opioid Epidemic: Positioning Providers to Influence Policy and Improve Public Health.Focus (American Psychiatric Publishing) · 2025Article
- Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review.Journal of telemedicine and telecare · 2025Article
- Telemedicine-delivered treatment for substance use disorder: A scoping review.Journal of telemedicine and telecare · 2025Article
- Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study.Addiction science & clinical practice · 2025Article
- Regulation and Compliance in Telemedicine: Viewpoint.Journal of medical Internet research · 2025Article
- Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study.Addiction science & clinical practice · 2025Article
- Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.Journal of substance use and addiction treatment · 2024Observational
- Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India.Indian journal of psychiatry · 2024Article
- Changes in opioid treatment programs and harm reduction provider services during the COVID-19 pandemic: Findings from 10 states.Psychological services · 2024Article
- Digital health interventions to support women with opioid use disorder: A scoping review.Drug and alcohol dependence · 2024Article
- Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.Harm reduction journal · 2024Article
- Barriers to retention in medications for opioid use disorder treatment in real-world practice.Journal of substance use and addiction treatment · 2024Observational
- Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Brian ChanDepartment of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.ORCID 0000-0003-1025-6619
Christina BougatsosDepartment of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.
Kelsey C PriestOHSU School of Medicine, MD/PhD Program, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-3929-8177
Dennis McCartyDepartment of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.ORCID 0000-0001-9014-2894
Sara GrusingDepartment of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.
Roger ChouDepartment of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.
Oregon Health & Science University · US
Funding
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6MOregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0MIdentifying High Utilizing Patients with Opioid Use Disorder to Engage in Primary CareK23DA053390 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Brian Chan · 2022 to 2026
$886kVariation in the Use of Opioid Agonist Treatment in HospitalsF30DA044700 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PRIEST, KELSEY CAROLINE · 2017 to 2020
$186kNIDA NIH HHS F30 DA044700NIDA NIH HHS K23 DA053390NIDA NIH HHS UH3 DA044831
Abstract
PubMed holds no abstract for this paper.
Indexed as
BuprenorphineCOVID-19 Drug TreatmentOpioid-Related DisordersPregnancy Complications, InfectiousTelemedicineAnalgesics, OpioidFemaleHumansMethadoneOpiate Substitution TreatmentPandemicsPregnancySARS-CoV-2United StatesAnalgesics, OpioidBuprenorphineMethadonebuprenorphineCOVID-19methadoneopioid use disorderTelemedicine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.